IL292689A - Topical compositions comprising irak4 inhibitors for use in treating dermatological conditions characterised by inflammation - Google Patents

Topical compositions comprising irak4 inhibitors for use in treating dermatological conditions characterised by inflammation

Info

Publication number
IL292689A
IL292689A IL292689A IL29268922A IL292689A IL 292689 A IL292689 A IL 292689A IL 292689 A IL292689 A IL 292689A IL 29268922 A IL29268922 A IL 29268922A IL 292689 A IL292689 A IL 292689A
Authority
IL
Israel
Prior art keywords
inflammation
treatment
skin conditions
conditions characterized
topical preparations
Prior art date
Application number
IL292689A
Other languages
English (en)
Hebrew (he)
Original Assignee
Dermirainc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Dermirainc filed Critical Dermirainc
Publication of IL292689A publication Critical patent/IL292689A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/10—Anti-acne agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Dermatology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Cosmetics (AREA)
IL292689A 2019-11-05 2022-05-02 Topical compositions comprising irak4 inhibitors for use in treating dermatological conditions characterised by inflammation IL292689A (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201962931132P 2019-11-05 2019-11-05
US202063046143P 2020-06-30 2020-06-30
PCT/US2020/059200 WO2021092239A1 (en) 2019-11-05 2020-11-05 Topical compositions comprising irak4 inhibitors for use in treating dermatological conditions characterised by inflammation

Publications (1)

Publication Number Publication Date
IL292689A true IL292689A (en) 2022-07-01

Family

ID=73654894

Family Applications (1)

Application Number Title Priority Date Filing Date
IL292689A IL292689A (en) 2019-11-05 2022-05-02 Topical compositions comprising irak4 inhibitors for use in treating dermatological conditions characterised by inflammation

Country Status (9)

Country Link
US (1) US20230125380A1 (https=)
EP (1) EP4054573A1 (https=)
JP (1) JP2023500707A (https=)
CN (2) CN118806758A (https=)
AU (1) AU2020380921A1 (https=)
BR (1) BR112022008610A2 (https=)
CA (1) CA3159624A1 (https=)
IL (1) IL292689A (https=)
WO (1) WO2021092239A1 (https=)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA3186630A1 (en) * 2020-06-30 2022-01-06 Dermira, Inc. Irak4 inhibitors and topical uses thereof
CN118530374B (zh) * 2023-06-02 2025-11-04 东北农业大学 犬成纤维细胞生长因子21融合蛋白制备及其在治疗特应性皮炎中的用途

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN105899505B (zh) 2013-11-08 2018-08-28 武田药品工业株式会社 用于治疗自身免疫病症的吡唑
BR112018000624A2 (pt) * 2015-07-15 2018-09-18 Aurigene Discovery Technologies Limited compostos de indazol e azaindazol como inibidores de irak-4
WO2017205762A1 (en) * 2016-05-27 2017-11-30 Pharmacyclics Llc Inhibitors of interleukin-1 receptor-associated kinase
EP3727428A1 (en) * 2017-12-20 2020-10-28 Translate Bio, Inc. Improved composition and methods for treatment of ornithine transcarbamylase deficiency
IL315310A (en) * 2017-12-26 2024-10-01 Kymera Therapeutics Inc Irak degraders and uses thereof
CA3186630A1 (en) * 2020-06-30 2022-01-06 Dermira, Inc. Irak4 inhibitors and topical uses thereof

Also Published As

Publication number Publication date
AU2020380921A1 (en) 2022-05-26
US20230125380A1 (en) 2023-04-27
JP2023500707A (ja) 2023-01-10
CN114929223A (zh) 2022-08-19
EP4054573A1 (en) 2022-09-14
CA3159624A1 (en) 2021-05-14
CN118806758A (zh) 2024-10-22
BR112022008610A2 (pt) 2022-08-09
WO2021092239A1 (en) 2021-05-14

Similar Documents

Publication Publication Date Title
IL283042A (en) Compounds and compositions for treating conditions associated with nlrp activity
PT3902803T (pt) Inibidores aza-heterobicíclicos de mat2a e métodos de utilização para o tratamento do cancro
PL3383363T3 (pl) Preparaty farmaceutyczne do stosowania miejscowego do leczenia stanów związanych z zapaleniem
IL268850A (en) Combinations of a 4-pyrimidinesulfamide derivative with active ingredients for the treatment of endothelin related diseases
MA52575A (fr) Pansement pour le traitement de la peau endommagée
EP3873897C0 (en) N-BENZOYL-PHENYLALANINE DERIVATIVES AS INTEGRIN ALPHA4BETA7 INHIBITORS FOR THE TREATMENT OF INFLAMMATORY DISEASES
AU2019410432B2 (en) Quinoline derivatives for use in the treatment of inflammation diseases
HUE063145T2 (hu) Deuterált vegyületek rákos megbetegedések kezelésében történõ alkalmazásra
PL3429571T3 (pl) Kombinacje inhibitorów lsd1 do zastosowania w leczeniu chorób nowotworowych
DK3704108T3 (da) Irak4-hæmmer i kombination med en bcl-2-hæmmer til anvendelse i cancerbehandling
ZA201902275B (en) Topical dressing composition for the treatment of damaged skin tissue
IL269158A (en) Compositions and methods for treating inflammatory diseases
HUE059050T2 (hu) Aminosavakat tartalmazó készítmények mitokondriális rendellenességgel összefüggõ betegségek kezelésében történõ alkalmazásra
EP4003299A4 (en) Treatment of skin disorders with topical tapinarof-egfr inhibitor compositions
IL272253A (en) Compositions and methods for treatment of inflammatory conditions and diseases of the skin
SG11202002214QA (en) Topical semisolid composition containing an antimicrobial agent and pirfenidone for the treatment of chronic skin damage
IL287704A (en) Use of cannabidiol in the treatment of tuberous sclerosis complex
IL289371A (en) Methylthioninium for use in the treatment of synaptopathies
MX394452B (es) Inhibicion de la actividad de olig2.
EP3346989A4 (en) STABLE LIPOSOMAL FORMULATIONS OF RAPAMYCIN AND RAPAMYCIN DERIVATIVES FOR THE TREATMENT OF CANCER
IL292689A (en) Topical compositions comprising irak4 inhibitors for use in treating dermatological conditions characterised by inflammation
EP3316874A4 (en) TOPICAL AND INJECTABLE RESIQUIMOD COMPOSITIONS FOR THE TREATMENT OF NEOPLASTIC GUM DISEASES
EP3761952C0 (en) TOPICAL SKIN CARE COMPOSITIONS
LT3880186T (lt) Pd-1 inhibitorių skyrimas į pažeidimo vietą odos vėžiui gydyti
MX394015B (es) Inhibición de la actividad de la olig2.